<?xml version='1.0'?>
<!DOCTYPE art SYSTEM 'http://www.biomedcentral.com/xml/article.dtd'>
<art>
   <ui>bcr1104</ui>
   <ji>BCJ</ji>
   <fm>
      <dochead>Poster Presentation</dochead>
      <bibl>
         <title>
            <p>Genetic polymorphisms in the 5' flanking region of glutathione S-transferase P1 affect promoter methylation</p>
         </title>
         <aug>
            <au id="A1">
               <snm>R&#248;nneberg</snm>
               <fnm>JA</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A2">
               <snm>Tost</snm>
               <fnm>J</fnm>
               <insr iid="I2"/>
            </au>
            <au id="A3">
               <snm>Grenaker-Aln&#230;s</snm>
               <fnm>GI</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A4">
               <snm>S&#248;rlie</snm>
               <fnm>T</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A5">
               <snm>Kristensen</snm>
               <fnm>T</fnm>
               <insr iid="I3"/>
            </au>
            <au id="A6">
               <snm>Gut</snm>
               <fnm>I</fnm>
               <insr iid="I2"/>
            </au>
            <au id="A7">
               <snm>B&#248;rresen-Dale</snm>
               <fnm>A-L</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A8">
               <snm>Kristensen</snm>
               <fnm>VN</fnm>
               <insr iid="I1"/>
            </au>
         </aug>
         <insg>
            <ins id="I1">
               <p>Department of Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway</p>
            </ins>
            <ins id="I2">
               <p>Centre National de Genotypage, Evry, France</p>
            </ins>
            <ins id="I3">
               <p>Department of Molecular Biosciences, University of Oslo, Norway</p>
            </ins>
         </insg>
         <source>Breast Cancer Research</source>
         <supplement>
            <title>
               <p>The Third International Symposium on the Molecular Biology of Breast Cancer</p>
            </title>
            <sponsor>
               <note>Affymetrix, Agilent Technologies, Applied Biosystems, AstraZeneca, Novartis Oncology, Pfizer, Roche Diagnostics (Main Sponsors).</note>
            </sponsor>
            <note>Meeting abstracts</note>
         </supplement>
         <conference>
            <title>
               <p>The Third International Symposium on the Molecular Biology of Breast Cancer</p>
            </title>
            <location>Molde, Norway</location>
            <date-range>22&#8211;26 June 2005</date-range>
         </conference>
         <issn>1465-5411</issn>
         <pubdate>2005</pubdate>
         <volume>7</volume>
         <issue>Suppl 2</issue>
         <fpage>P1.17</fpage>
         <xrefbib>
            <pubid idtype="doi">10.1186/bcr1104</pubid>
         </xrefbib>
      </bibl>
      <history>
         <pub>
            <date>
               <day>17</day>
               <month>6</month>
               <year>2005</year>
            </date>
         </pub>
      </history>
   </fm>
   <bdy>
      <sec>
         <st>
            <p/>
         </st>
         <p>Glutathione-S-transferase P1 (GSTP1) is involved in thiol-mediated detoxification and breakdown of reactive oxygen species created by anticancer drug exposure. GSTP1 is also an inhibitor of c-Jun N-terminal kinase 1, a kinase involved in stress response, apoptosis and cellular proliferation. Hypermethylation of the <it>GSTP1 </it>promoter has been associated with gene silencing in prostate cancer, kidney cancer, and breast cancer, among others. Although frequently described, the mechanism underlying promoter hypermethylation of the <it>GSTP1 </it>gene is poorly understood. It has been reported that an ATAAA repeat of the <it>GSTP1 </it>promoter separates methylated from unmethylated CpGs in normal prostate tissue <abbrgrp><abbr bid="B1">1</abbr></abbrgrp>. These separate methylation domains are lost in prostate cancer, and methylation extends throughout the whole promoter region. It has been proposed that hypermethylation of <it>GSTP1 </it>requires a combination of gene silencing and random seeds of methylation in prostate cancer cells, and that these combinatorial effects lead to histone deacetylation and subsequent chromatin remodeling <abbrgrp><abbr bid="B2">2</abbr></abbrgrp>. To further elucidate the mechanisms underlying the hypermethylation of the <it>GSTP1 </it>promoter, we genotyped the (ATAAA) repeat and the linked SNPs in positions -354, -288, -287 and -282 in the <it>GSTP1 </it>promoter and we performed methylation analysis using mass spectrometry in tumor DNA from 82 breast cancer patients. The role of the different allelic variants on methylation status of the <it>GSTP1 </it>promoter and expression levels was assessed. We quantitatively determined the methylation status of six CpGs spanning the transcription start site of the GSTP1 promoter: -22, +8, +14, +38, +47 and +55. The average percentage methylation for each individual CpG for the 82 tumor samples analyzed was 16.9%, 30.3%, 18.2%, 21.2%, 18.6% and 8.1%, respectively. The average percentage methylation for all CpGs in all tumor samples was 19%. There was a correlation between the degree of methylation of the individual CpGs and their neighboring CpGs (<it>P </it>&lt; 0.001). When correlating the extent of methylation to the mRNA levels previously assessed by whole genome gene-expression profiling of the same tumors, a significant inverse correlation was observed (<it>P </it>&lt; 0.01). The methylation status of the three CpGs closest to the transcriptional start site was more highly associated with the level of <it>GSTP1 </it>mRNA expression than the CpGs further downstream of the +1 site. Furthermore, we observed differences in the degree of <it>GSTP1 </it>promoter methylation between the different tumor subclasses defined by whole-genome microarray analysis <abbrgrp><abbr bid="B3">3</abbr></abbrgrp>. The methylation of the <it>GSTP1 </it>promoter was significantly lower in the basal subtype compared with the luminal subtype, which corresponded to elevated <it>GSTP1 </it>mRNA levels in the basal subtypes <abbrgrp><abbr bid="B4">4</abbr></abbrgrp>. We further analyzed the impact of the most frequent haplotype structure of the <it>GSTP1 </it>promoter in relation to the extent of methylation, and a correlation was observed (<it>P </it>= 0.003) suggesting that haplotype structures can affect <it>de novo </it>methylation of adjacent sequences.</p>
      </sec>
   </bdy>
   <bm>
      <refgrp>
         <bibl id="B1">
            <aug>
               <au>
                  <snm>Millar</snm>
                  <fnm>DS</fnm>
               </au>
               <etal/>
            </aug>
            <source>J Biol Chem</source>
            <pubdate>2000</pubdate>
            <volume>275</volume>
            <fpage>24893</fpage>
            <lpage>24899</lpage>
            <xrefbib>
               <pubidlist>
                  <pubid idtype="doi">10.1074/jbc.M906538199</pubid>
                  <pubid idtype="pmpid" link="fulltext">10779522</pubid>
               </pubidlist>
            </xrefbib>
         </bibl>
         <bibl id="B2">
            <aug>
               <au>
                  <snm>Stirzaker</snm>
                  <fnm>C</fnm>
               </au>
               <etal/>
            </aug>
            <source>Cancer Res</source>
            <pubdate>2004</pubdate>
            <volume>64</volume>
            <fpage>3871</fpage>
            <lpage>3877</lpage>
            <xrefbib>
               <pubid idtype="pmpid" link="fulltext">15172996</pubid>
            </xrefbib>
         </bibl>
         <bibl id="B3">
            <aug>
               <au>
                  <snm>Perou</snm>
                  <fnm>CM</fnm>
               </au>
               <etal/>
            </aug>
            <source>Nature</source>
            <pubdate>2000</pubdate>
            <volume>406</volume>
            <fpage>747</fpage>
            <lpage>752</lpage>
            <xrefbib>
               <pubidlist>
                  <pubid idtype="doi">10.1038/35021093</pubid>
                  <pubid idtype="pmpid" link="fulltext">10963602</pubid>
               </pubidlist>
            </xrefbib>
         </bibl>
         <bibl id="B4">
            <aug>
               <au>
                  <snm>Troester</snm>
                  <fnm>MA</fnm>
               </au>
               <etal/>
            </aug>
            <source>Cancer Res</source>
            <pubdate>2004</pubdate>
            <volume>64</volume>
            <fpage>4218</fpage>
            <lpage>4226</lpage>
            <xrefbib>
               <pubid idtype="pmpid" link="fulltext">15205334</pubid>
            </xrefbib>
         </bibl>
      </refgrp>
   </bm>
</art>
